# Open Orphan ‘Venn will deliver significant additional revenue’, announces contract extension with Carna Biosciences

- Link: https://www.directorstalkinterviews.com/open-orphan-venn-will-deliver-significant-additional-revenue-announces-contract-extension-with-carna-biosciences/412957572
- Published: 2021-02-01T07:37:15+00:00
- Author: Giles

**Open Orphan plc** ([LON:ORPH](https://www.directorstalkinterviews.com/company/open-orphan-plc/orph.l)),
a rapidly growing specialist pharmaceutical services clinical research organisation(
CRO) and a world leader in vaccine and antiviral testing using human challenge clinical
trials, announces a further contract renewal with Carna Biosciences, Inc., extending
its integrated drug development consultancy services with Venn Life Sciences, part
of Open Orphan plc.

> **Executive Chairman Cathal Friel told DirectorsTalk Interviews,** “We are announcing
> the signing of a contract extension with Carna Biosciences Inc by our Venn team
> in the Netherlands which will deliver significant additional revenue for Venn 
> for the coming 12 months and is a clear sign of how we are growing and expanding
> the Venn business substantially. Carna is a clinical-stage biopharmaceutical companywhich
> focuses on the discovery and development of innovative therapies to treat serious
> unmet medical needs. Venn will be providing Chemistry, Manufacturing & Control(
> CMC), Non-Clinical, Clinical and also Regulatory consultancy services to this 
> client for two of their leading drug development programmes.  
> Venn and Carna have built up a good working relationship over several years and
> this extension further demonstrates our ability to collaborate successfully with
> our clients and provide a service that results in repeat business.”

Carna Biosciences is a clinical-stage biopharmaceutical company which focuses on
the discovery and development of innovative therapies to treat serious unmet medical
needs, focusing on small molecule drugs. The renewal of this contract is expected
to deliver significant revenue for Venn over the next twelve months.

The Venn team in the Breda office in the Netherlands, will provide Chemistry, Manufacturing&
Control (CMC), Non-Clinical, Clinical and Regulatory consultancy services to this
client for two of the client’s leading development programmes. This successful collaboration
has been extended until the end of December 2021.

**Cathal Friel, Executive Chairman of Open Orphan, said: **“The extension of this
contract further demonstrates our ability to collaborate successfully with our clients
and provide a service that results in repeat business. Venn and Carna have built
up a good working relationship over a period of several years where both parties
closely collaborated on drug development planning and its execution through consultancy
services contracts. We look forward to delivering this contract for Carna in the
year ahead.”

**Masaaki Sawa, Ph.D., Chief Scientific Officer and Head of Research and Development
at Carna Biosciences, said: **“The partnership with Venn Life Sciences complements
our clinical development team and underlines our commitment to become a clinical
stage company. By continuing the collaboration with the Venn team, we will accelerate
our drug development.”

Share on:
